论文部分内容阅读
Liquid biopsies,examinations of tumor components in body fluids,have shown promise for predicting clinical outcomes.To evaluate tumor-associated genomic and genetic variations in plasma cell-free DNA (cfDNA) and their associations with treatment response and overall survival,we applied whole genome and targeted sequencing to examine the plasma cfDNAs derived from 20 patients with advanced prostate cancer.